Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00306748
Status:
COMPLETED
Last Update Posted:
2009-03-24
First Post:
2006-03-20
Brief Title:
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
Sponsor:
Ironwood Pharmaceuticals Inc
Organization:
Ironwood Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Multicenter Double-Blind Parallel-Design Phase 2 Trial of Oral MD-1100 Acetate Administered for 14 Days Once Daily at 100 ug 300 ug 1000 ug or Placebo to Patients With Chronic Constipation
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and gastrointestinal pharmacodynamics stool frequency stool consistency stool ease of passage stool completeness of evacuation of MD-1100 acetate administered daily for 14 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None